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Advanced models in prostate cancer research 651. IntroductionProstate cancer (PCa) is the most commonly diagnosed
cancer and the second most common cause of cancer-
related mortality among males in the United States, with a
lifetime risk of one in six [1,2]. Androgen-deprivation
therapy (ADT) is the first-line therapy to improve survival
and reduce morbidity in primary or metastatic PCa. Current
measures for combating the disease are partially effective,
but they are usually not specific for PCa, causing unwanted
side effects. The side effects can be serious and leave the
possibility for recurrence in a more aggressive, androgen-
independent form [3]. Further treatments for castration-
resistant prostate cancer (CRPC) after ADT remain a chal-
lenge because patients’ performance status often pro-
gressively declines [4]. Although researchers have
identified defined histological alterations in PCa, the nature
of this genetically heterogeneous disease has restricted the
identification of novel alternatives of genes that can be
used as therapeutic targets [5].
The prostate is a canalized ductaleacinar structure
that develops from the embryonic urogenital sinus (UGS)
to form a predominantly fibromuscular phenotype [6]. The
ductaleacinar structure is constituted with tall columnar
secretory luminal cells and a flattened basal epithelium
[7,8]. The expression of cytokeratins (CK) and character-
istic biomarkers are distinct in prostate basal and luminal
epithelial cells. Basal cells express CK5, CK14 and tumor
suppressor p63, whereas luminal cells express CK8, CK18
and the androgen receptor (AR) as well as prostate-
specific antigen (PSA) [9,10]. Other basal cell markers
including B cell lymphoma/leukemia-2 (BCL-2), epidermal
growth factor receptor (EGFR), and mesenchymal to
epithelial transition factor (MET) have also been reported
[11e14]. Prostate luminal and basal epithelia cells can be
generated from stem cells [15]. Luminal cells have long
been considered as the cellular origin of the majority of
PCa. However, recent studies suggested that prostate
basal stem and progenitor cells can also give rise to PCa
[16e20]. It has been proposed that mature luminal cells
and basal cells are developed independently and that
luminal cells are derived from self-renewing luminal stem
cells [21,22]. Based on several mouse studies, some have
proposed that fully differentiated luminal cells can display
benign or malignant proliferate characteristics in vivo
[23], but the mechanisms responsible for prostate luminal
epithelial colonial proliferation and regeneration remain
unclear.
Many oncogenes and tumor suppressor genes are
mutated across a large extent of PCa, such as Ras, Myc, p53
and phosphatase and tensin homolog deleted on chromo-
some ten (PTEN) [24e28]. Although these genes are
frequently altered in PCa, their role in tumor initiation and
progression is not known. However, most PCa contain a
usual set of “driver mutations”, thus unveiling multiple
oncogenic routes that are highly dependent on the disrup-
tion of specific pathways such as p38/MAPK, Notch and
PI3K/Akt [29e35].
The investigation of human prostate models has yielded
a better understanding of prostate oncogenesis and cellulardifferentiation. A few potential prostate models have been
established for how oncogenic disruption of particular dif-
ferentiation pathways can promote tumor initiation
[36,37]. Some estimate that the cells of origin are not
committed luminal or basal stem cells in PCa, but rather a
transient-intermediate cell, which is found in both human
and mouse prostate [38]. Accordingly, a deeper under-
standing of the cell of origin in PCa with appropriate
prostate models is needed, and being able to find more
sensitive ways to detect prostate tumors and predict tumor
aggressiveness is also a challenge.
Prostate stem and progenitor cells are defined by their
ability to undergo self-renewal and multipotent differen-
tiation. It is important to develop some models of prostate
stem and progenitor cells for understanding the molecular
mechanisms of prostatic development, maturation, and
malignant transformation [9,39]. In recent reports, scien-
tists established relevant in vivo models that examined
basal-derived cells for prostate regeneration [40]. Addi-
tionally, there are few available cell lines that could inform
prostatic biological status and that can be used to examine
prostate carcinogenesis. As a consequence, there is an
instant need for prostate cell lines that recapitulate the
different phenotypes identified in actual human tissue
samples. Tissue recombination is a valuable instrument for
analyzing the functional remodeling of human prostatic
tissues in immunodeficient mouse models [41]. Unfortu-
nately, most of the present studies lack understanding of
the detailed mechanisms driving PCa. In this review we
describe several established PCa models that could poten-
tially drive new specific therapeutic agents for increasing
efficacy and reducing side effects.2. Transgenic mouse models: PSA-Cre-ERT2/
PTEN mouse line
The identification of specific cancer biomarkers, such as
Ras, Myc, p53 and PTEN, lie in the center of current chal-
lenges in the recognition of tumor initiation, prediction of
prognosis, and design of targeted therapies. Down-
regulation of PTEN was first recognized in the late 1990s
in about 10% of primary prostate tumors and in 65% of
metastatic tumors [42e44]. There is now abundant infor-
mation illustrating down-regulation of PTEN via mutation,
transcriptional repression, or deletion in many cancers,
including PCa [45,46]. PTEN is one of the most common
genetic transformations that can regulate PI3K/Akt path-
ways to influence cellular function [47,48]. It was also re-
ported that the down-regulation of PTEN was associated
with poor prognosis in PCa patients [43,49,50]. Notably,
many people concluded that the tissues from castration-
sensitive patients expressed high PSA, the marker of
differentiated luminal cells. Following injection of
immunodeficient mice, both PSA-negative and PSA-
positive cell populations displayed tumor-initiating capa-
bility, but the PSA-positive population generated more and
larger tumors [51].
Due to the lack of in vitro models for studying human
oncogenesis, the translation of these genetic modifications
in the mouse to understand the diseases of prostate are
66 Y. Huang et al.highly informative. Mouse models are helpful for genetic
experiments without the same ethical limitations as
humans [52,53]. Transgenic mouse models rely on cycliza-
tion recombination enzyme (Cre) activity via “cell-specific”
promoters, such as K5, K8 or Nkx3.1 [21,54]. It also has
been reported that specific expression of bacteriophage P1
site-specific Cre recombinase is the key formation for
conditional gene targeting in mouse. A DNA segment,
flanked by two Lox P sites (floxed DNA), can be excised
efficiently during the Cre recombinase [55,56]. The repro-
duction of transgenic animal models for human diseases in
different organs depends on the efficient introduction of
the mutations in a gene over a period of time [57,58]. With
conditional knockouts, we can avoid embryonic lethality
with conventional gene knockout techniques. Choi et al.
[25], for example, established inducible Cre-LoxP-
mediated genetic cell-lineage tracing to characterize the
differentiation potential of luminal and basal progenitors in
adult mouse prostates [54,59]. In the same paper, they
argued that both basal and luminal cells were unipotent
and self-sustained lineages which could generate indepen-
dent epithelial cell types in adult mouse prostate. More
importantly, they demonstrated that PTEN knockdown in
either the basal or luminal cell lineages could lead to the
occurrence of PCa exhibiting different susceptibility. In the
another article [60], they reported success in the genera-
tion and detailed molecular characterization of seven
human-derived PCa organoid lines derived from diverse
disease sites including circulating tumor cells (CTC). These
lines harbor copy number signatures of primary PCa,
including SPOP mutation, PTEN loss, TMPRSS2-ERG inter-
stitial deletion, as well as alterations commonly found in
CRPC, including TP53, PIK3R1, FOXA1 and several chro-
matin modifier mutations. Better understanding of the
functions of specific genes in PCa will be required to vali-
date suitable transgenic mouse models.
In our previous studies, we reported that a 6.0-kb PCR
amplified DNA fragment containing three androgen
response elements (ARE), one enhancer and the proximal
promoter of human prostate-specific antigen (hPSA) gene
was cloned into the SalI site of pGS-Cre-ERT2 to generate
pPSA-Cre-ERT2 [61,62]. The DNA fragment is fused to the
Cre-ERT2 recombinase, which is fused to a mutated ligand-
binding domain (LBD) of the human estrogen receptor (ER)
containing the G400V/M543A/L544A triple mutation [62].
These transgenic mice mimic the expression of the human
endogenous androgen-regulated PSA gene with specific Cre
recombinase in prostate luminal epithelial cells [19,63].
PSA-Cre-ERT2 mice were cross-bred with floxed homozygous
PTEN mice which have been described in Suzuki’s research
[10] to generate double transgenic PSA-Cre-ERT2/PTEN
mice. Tamoxifen was injected ip daily for 5 consecutive
days (D1eD5) to 8-week-old mice [64,65]. At this point,
conditional PTEN floxed alleles were generated in the mice,
and the expression of PTEN was subsequently ablated
through breeding with transgenic mice which express the
Cre recombinase under the control of the PSA promoter
[66].
The generation of PSA-Cre-ERT2 mice allows us to target
floxed genes selectively in prostate luminal epithelial cells
and to coordinate the number of epithelial cells that aregenetically altered. Our PSA-Cre-ERT2/PTEN mouse model
with ablated tumor suppressor gene PTEN closely dupli-
cates the progression of human PCa. In a previous study,
after PTEN ablation, we found the prostate epithelium
displayed significant cytologic atypia in 4 weeks and
prostatic intraepithelial neoplasia (PIN) in 2e3 months. It
is noteworthy that the two kinds of precancerous lesions
usually occur in the dorsolateral lobe, which is the most
similar genetically to the human prostate. After 10
months, some precancerous lesions begin to form tumors
[66]. In another report using PSA-Cre-ERT2-based genetic
lineage marking/tracing in mice, preexisting luminal
epithelial cells were shown to be a source of regenerated
luminal epithelial cells in the adult mouse prostate. That
study demonstrated the survival and proliferation of
luminal epithelial cells in response to castration and
androgen replacement in transgenic mouse models [67].
According to these results, we can assume that the PSA-
Cre-ERT2 transgenic mouse will be a valuable tool for
clarifying the functions of particular genes in prostate
development and carcinogenesis, and also an important
measure to study preventive and therapeutic approaches
in vivo. This model represents a clinically relevant model
of PCa development and progression.
In some aspects, investigations in transgenic mice are
limited. For example, signaling mechanisms for differen-
tiation in human and mouse prostate epithelial cells may
be different. Our PSA-Cre-ERT2 transgenic model, showed
no distant metastases even after PTEN ablation for
extended periods, indicating that progression to metas-
tasis requires an additional mutation or mutations [66].
Taken together, the present data show that our transgenic
mouse models produce the initial phases of progression of
human PCa.3. Human prostate cancer-mouse anterior
prostate (AP)-orthotopic xenografting (OX)
model (AP-OX)
It is widely recognized that the majority of PCa deaths are
due to the tumor metastasis, especially skeletal metasta-
ses [68], but modeling this process in mice has proven
difficult. Furthermore, PCa induces an osteoblastic reac-
tion within the bone, which is rarely observed in other
tumors. What causes bone metastasis and osteoblastic le-
sions in PCa remains unclear. The incurability of PCa is not
only related to the tumor itself, but also to the interactions
between tumor cells and their microenvironment. This
tumor microenvironment produces various cell types,
growth factors and cytokines, and numerous extracellular
matrix (ECM) components. The interactions between tu-
mors cells and their microenvironment are required for
invasion, angiogenesis, and metastasis to other organs
[69,70]. Factors in the microenvironment can promote
epithelial-mesenchymal transition (EMT) via up-regulation
of specific transcription factors. The cancer cells present
mesenchymal phenotypes by EMT programming and then
cleave the ECM, exit the tumor microenvironment and
intravasate into blood vessels to travel to distal organs
[71]. Much attention has been given to in vivo animal
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number of preclinical mouse models of PCa are currently
available, including many transgenic mouse models and
fewer orthotopic xenografting mouse models [72,73].
Orthotopic prostate xenografting mouse models produce
more heterogeneous cohorts of tumors and controlled ap-
proaches than transgenic mouse models [74]. Human PCa
orthotopic implantation into the prostate of immunodefi-
cient mice has been proven as a vital method for PCa
research.
For the orthotopic xenografting model, subconfluent
luciferase-expressing tumor cells such as PC3 or LNCaP are
mixed with neutralized collagen gel, implanted into the
mouse anterior prostate (AP) lobe through a lower midline
laparotomy incision, and then injected subcutaneously into
the right flank of 10-week-old nude male mice [74e76].
After xenografting, tumor growth is detected by whole-
animal bioluminescent imaging performing using an
in vivo imaging system (IVIS) biweekly [77]. Additionally,
osseous metastases are monitored by X-ray in these
orthotopic xenografting models [76].
The AP-OX models in vivo have been successfully used
for studying the biological functions of some genes
involved in metastasis in PCa. Hafeez et al. [75] demon-
strated that the importance of Plumbagin (PL) for cancer
cell growth, invasion and metastasis using an AP-OX
model. Xiang et al. [77] presented that SPARCL1
decreased invasive and metastatic progression signifi-
cantly in OX models. Additional studies of these tumor-
related genes will be valuable for determining its mech-
anisms of metastasis and generating potential anti-
metastatic agents for the treatment of PCa. Alterna-
tively, AP-OX models are of great benefit for the study of
the curative effects of novel clinical trial drugs on tumor
cell proliferation and regional lymph node metastasis
particularly [74]. This new model better recapitulates the
clinical situation, adding significance to the study of the
biological characteristics of bone-metastatic PCa and for
exploitation of specific treatments.
Human prostate cancer-mouse AP-OX models, in
contrast to transgenic mouse models, provide a beneficial
alternative approach for understanding the specific in-
teractions between various molecularly and genetically
altered tumor cells and the tumor microenvironment
[72,78e80]. These human tumor xenografting models retain
the growth and histopathological features characteristic of
the original cancers and have been used for rapid screening
of potential therapeutics. In addition, orthotopic implan-
tation united with subsequent harvesting at metastatic
sites can draw upon mutations of tremendous clinical
relevance to the metastatic process [81]. In comparison to
ectopic subcutaneous tumor models, the OX models can
more precisely reconstitute a tumor microenvironment that
influences the phenotypes of tumor cells, as originally
proposed by Stephen Paget’s “seed and soil” hypothesis and
affirmed by numerous others [82]. In summary, human
prostate cancer-mouse AP-OX greatly complement trans-
genic mouse models, providing valuable tools to study PCa
progression more deeply.
Unfortunately, some human tumor xenografting models
are associated with exceedingly low tumor take rates andonly successful in case of highly advanced malignancies
[83]. These deficiencies reduce the usefulness of such
models for studies of PCa metastasis and restrict the pre-
dictive power of such models with regard to patient re-
sponses to anticancer drugs in the clinic.4. NHPrE1- and BHPrE1-based tissue
recombination-xenografting model
The mechanisms of self-renewal and multipotent differen-
tiation in prostate stem and progenitor cells are important
to understand the molecular mechanisms of prostate
development as well as cancer initiation and maturation
[9,39]. It is also important to understand the role of
inflammation on benign growth and tumorigenesis of human
cells [23,84]. However, there are not enough stable benign
cell lines available to verify the function of stem and pro-
genitor cells in prostatic development and tumor initiation.
Accordingly, the development of prostate epithelial cell
lines that adequately recapitulate benign histology as well
as the various tumor phenotypes is sorely needed. Tissue
recombination is a valuable tool for studying the functional
remodeling of human prostate [85]. In recent years,
immortalized human prostate epithelial (HPrE) cell lines
including BPH-1 have been reported to recapitulate the
functions of human prostatic tissues [86]. However, BPH-1
cells often demonstrate squamous hyperplastic differenti-
ation in tissue recombinants and inaccurately recapitulate
prostatic development [87].
To meet this challenge we developed two novel spon-
taneously immortalized cell lines from adult non-
tumorigenic human prostate epithelium, NHPrE1
(CD133high/CD44high/OCT4high/PTENhigh) and BHPrE1
(p63high/p53high/(p21WAF1)high/RBhigh). NHPrE1 cells were
characterized as a putative progenitor cell line, and BHPrE1
cells were characterized as a putative epithelial interme-
diate cell line [88].
Recombination of human prostate epithelial stem cells
with rat embryonic urogenital sinus mesenchyme (UGM)
functionally re-establishes the stem cell niche and allows
for the assaying of stem cell properties in vivo. The struc-
tures and phenotypes of the recombinants made with our
spontaneously immortalized cell lines depended on the
ratio and nature of implanted epithelial cells [89] and
relied on UGM similar to previous reports [85].
The NHPrE1 and BHPrE1 cells are able to regenerate
benign secretory ductaleacinar architecture in vivo, which
contains both basal and luminal epithelial cells expressing
appropriate CK profiles [90e92]. Because the NHPrE1 are
more of a progenitor cell, regeneration usually only needs a
minimum of 10 cells, whereas the more intermediate
BHPrE1 cells required at least 200 000 seeding cells. It was
noted that the human prostatic biomarkers including PSA,
Nkx3.1, androgen receptor (AR), and 15-lipoxygenase-2
(15-LOX-2) were expressed in the regenerated epithelia
appropriately [88]. Accordingly, the NHPrE1 and BHPrE1 cell
lines represent potentially significant tools in which to
investigate the mechanisms associated with human pros-
tatic regeneration, pathogenesis, and carcinogenesis. As
68 Y. Huang et al.such, these cell lines represent potentially useful models in
which to start to investigate mechanisms associated with
both benign and malignant disease.
5. Prostatic organoid culture
There have been unprecedented developments in the
utilization of human tissue surrogates in vitro during the
past years. Despite many attempts by numerous in-
vestigators, however, it has been difficult to increase the
number of available cell lines in public cell line re-
positories with less than 10 for PCa [93,94]. The under-
representation of PCa cell line models for research stems
from the difficulty in propagating tumor cells for a long
time in vitro. In order to represent the spectrum of clin-
ical genotypes of PCa, new cell lines which display the
observed clinical phenotypes are urgently required [95].
Adult stem and progenitor cells can be embedded in a
special three-dimensional (3D) matrix without stroma and
allowed to self-organize. Such ‘3D’ culture systems not
only contain analogs of ECM, but also mix with some
conditions that enhance the differentiation, proliferation
and survival of stem or progenitor cells [96]. The gener-
ated organoids represent the biological characteristics of
native epithelium much better than the traditional PCa
cell lines [97].
The pseudostratified epithelium in the prostate gland
consists of basal and luminal cells. In the tissue
recombination-xenografting models mentioned above, the
basal cells reconstitute a whole prostate gland and luminal
cells can generate basal cells. The molecular details of
these transitions and whether they occur in humans re-
mains unclear. Prostate organoids in a 3D culture system
confirmed that both basal and luminal cells could generate
a complete multilayer prostate organoid and showed
luminal cells could generate both basal and luminal line-
ages [98]. Organoids generated from tumor or normal
prostate epithelium reveal adenoid architecture containing
luminal and basal cells, undergo expansion and express AR
[99]. Organoids are genetically stable and controllable, and
can be applied to mechanistic studies as a luminal multi-
lineage progenitor cell model.
The crucial breakthrough, however, is the optimization
of culture media that allows the infinite proliferation of
both benign and malignant prostate cells, maintains ge-
netic stabilization without drift and improves the genera-
tion of new cell lines with a higher success rate [98]. The
two ways for prostate organoid culture of isolated prostate
epithelial cells are floating in low-percentage Matrigel and
embedding within Matrigel. As prostate epithelium is sta-
tionary in vivo [24], the organoid culture medium should
contain available proliferative signals derived from the
stroma in vivo. In the floating method, prostate epithelial
cells are resuspended in prostate organoid culture medium,
consisting of epidermal growth factor (EGF), R-spondin 1,
Y-27632 (ROCK inhibitor), glutamax, dihydrotestosterone
(DHT), fetal bovine serum (FBS) and Matrigel. Interestingly,
in spite of the significance of interactions between
epithelia and mesenchyme in prostate regeneration and
organogenesis [100,101], the stroma for prostate epithelialself-renewal and differentiation can be replaced by soluble
factors in Matrigel, such as collagen IV and laminin. The
efficiency of organoid formation was evaluated by the
number of visible organoids after a week of growth. The
embedding method, on the other hand, was used to culture
organoids for drug treatment experiments with the culture
medium in presence or absence of drugs [99]. Human
prostate primary cells were seeded in growth factor
reduced Matrigel and cultured in medium containing growth
factors as above, with the addition of fibroblast growth
factor (FGF), prostaglandin E2 (PGE2), SB202190 (MAPK in-
hibitor), nicotinamide, and DHT [98].
Prostatic organoid culture, in comparison with other
experimental models, permits us to clarify the cellular
identity of human luminal stem or progenitor cells inimi-
tably. The culture conditions in Matrigel have proven that
these multipotential cells may also have neuroendocrine
cell repopulating potential. Besides, the characteristics of
the organoids are easily transformed with inhibitors or
retroviruses [102], providing an updated tool to study the
tumor behaviors on proliferation, invasiveness, and drug
sensitivity. In other approaches, it was shown that organoid
culture allowed efficient and stable growth of prostate
organoids with the genomic characteristics of tumor sam-
ples in PCa [60]. The appearance of organoid culture pro-
vides a simple, inexpensive, and robust alternative to
xenografting.
Prostate organoid culture can be established from
transgenic mouse models ranging from indolent (such as
Nkx3.1null) [21] to highly aggressive (such as HieMyc and
NPP53 [103,104]). Additionally, different malignant phe-
notypes of the prostate organoid cultures without stromal
cells could be detected, indicating that stromal cells are
not necessary for oncogenic transformation. Moreover,
organoid culture can reduce the gap between simple
cancer cell lines suitable for high-throughput screens and
complicated, but physiologically-relevant xenografts [97].
It will be used for drug screens and mechanistic studies of
therapeutic response and resistance in PCa [97,105].
Furthermore, primary prostatic cancer organoids might
be suitable for setting up a cryopreserved organoid li-
brary, and could be used for manufacturing targeted
drugs [106].
A possible shortcoming of organoid culture might be that
organoids from advanced cancers grow worse than those
from early tumors or normal tissue due to culture condi-
tions (optimized for normal culture) and reduce epithelial
integrity (EMT). On the other hand, organoids from early
tumors can be established at much higher success rates
than cancer cell lines or patient-derived tumor xenografts
(PDTX) allowing a better representation of the respective
cancer spectrum [97]. Therefore, prospective validation of
these prostatic organoid culture systems is required before
they can be widely adopted for advancing personalized
medicine.
6. Patient-derived xenografting (PDX) model
Preclinical models for drug trials are normally grounded in
immunodeficient mice carrying PCa cell line xenografts,
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mogeneity of established cell lines after long-term
culturing in vitro was observed, resulting in failure to
regenerate clinically-relevant heterogeneity [107]. Addi-
tionally, cell line-based xenografts rarely display the
organizational architecture of the original prostate ma-
lignancies and, consequently, do not accurately recapit-
ulate the intricate interactions between the PCa cells and
the tumor microenvironment [108]. Standardized and
representative preclinical models that recapitulate the
dynamics of PCa treatment are urgently required. In
theory, PDX models, based on direct transplantation of
fresh tumor specimens from PCa patients subcutaneously,
orthotopically or under the kidney capsule of immuno-
deficient mice (e.g., severe combined immunodeficiency
(SCID) mice, NOD scid gamma (NSG) mice), meet the
clinical demand [109].
PDX models have been used for the preclinical investi-
gation of various aspects of PCa including angiogenesis,
identification of castrate-resistant stem-like cells, effects
of anti-androgen therapies, and interactions between
tumor cells and the bone microenvironment [110e114]. At
the histopathological level, the PDX models maintain,
especially initially, the stromal components and tissue ar-
chitecture of the original tumors and are considered an
accurate representation of the complex biochemical milieu
in PCa [111,115]. At the cellular level, PDX models also
sustain inter-tumoral and intra-tumoral heterogeneity, as
well as the molecular characteristics of the original tumors,
including gene expression profiles [107,116e119], chromo-
somal copy number variants [116,120,121], and single-
nucleotide polymorphisms [117,122]. In clinical practice,
PDX have been used to predict and confirm drug responses
[123], exploit biological markers for standard and novel
antineoplastic drugs [111], and estimate the therapeutic
effects of patients [124]. Unfortunately, PDX are unfit for
in vitro cultures in regard to initial high throughput drug
screens [125]. Recently organoid culture has increased the
available preclinical tumor models by narrowing the gap
between cell lines and xenografts [126]. PDX provide a
prominent opportunity to capture some of the diversity,
complexity and therapeutic responsiveness of clinical PCa
[99,127]. Features such as a spectrum of histological char-
acteristics, responsiveness to androgens and relevant che-
mosensitivity enable preclinical modeling of the disease.
Furthermore, continuously updated implements that may
provide the ability to distinguish human and murine cells at
the histological [128] or gene expression level [129] provide
interesting opportunities to determine the contribution of
the tumor cell and host stroma to the pathobiology un-
derlying PCa.
Primary PCa samples were obtained from histologically
proven patients with different stages and therapeutic
results. The xenografts were derived from both androgen-
dependent and androgen receptor-negative castrate-
resistant PCa specimens [130,131]. Using xeongraft tech-
niques, patient specimens were transplanted into SCID
mice [83]. In brief, for sub-cutaneous transplantation, the
fragmented tumor sample was mixed with high concen-
tration Matrigel at the same volume and 0.1 mL wasinjected. For intra-femoral injection, the minced samples
were disaggregated by digestion in Accumax, filtered
through mesh filter sterilely, and then mixed with Matri-
gel. After that, a 15 mL mixture with about 50 000 cells
was injected [110]. To detect the growth of nascent
tumor, serum PSA, caliper measurement and other
experimental methods were used weekly [132]. The PDX
models are more accurate than cell line derived xeno-
grafts because they preserved the highly genotypical and
histopathological characteristics of the original clinical
samples [83,133].
However, similar to other PCa models in vitro, PDXs
have their inherent limitations and deficiencies. Firstly,
tumorehost interactions are not always conserved across
species and functional human immunity is mostly absent in
host mice [134]. To overcome the shortcoming, more so-
phisticated humanized models should be exploited by co-
grafting of tumor tissue along with bone marrow stem
cells of the same patient simulating the humanized im-
mune systems in mice [135,136]. Secondly, soaring ex-
penses and abundant human resources, compared to
traditional cell line-based systems, are imminently
required to promote the widespread use of PDX models
[137]. Widespread use of PDX models is limited by the time
and cost required to generate these models. It can take
between 4 and 8 months for detectable tumor growth in
mice [138]. Most notably, development of PDX models has
been hampered by low success rates when grown under
standard tissue culture conditions in vitro, mostly on ac-
count of poor vascularization in the transplantation site
[139]. However, these disadvantages are counteracted by
the outstanding clinical relevance of the PDX model, as it is
a most critical requirement for cancer models in drug ef-
ficacy and predictive biomarker development studies
[109,111].
7. Summary
In conclusion, a complement of transgenic mouse lines and
human tumor xenografting models are necessary to appro-
priately address individual components of PCa initiation
and progression (Table 1). While models in vitro allow a
more convenient and detailed analysis of cancer-related
pathways, it is becoming increasingly evident that the use
of different models may apply to the research of different
steps of tumor progression. The development of better
animal models that fully recapitulate the molecular events
as seen in human PCa is paramount to deciphering tumor
progression [140]. Clearly, a better pre-clinical balance
between improved in vitro mimicry and selecting models
that are more closely related to the clinical scenario is
urgently needed. Only through a better understanding of
oncogenesis can we find new methods to classify prostate
tumors and more accurately predict tumor aggressiveness.
We must develop PCa-related mouse lines or models that
could display comprehensive disease progression, and be
used for effective therapy development and testing. The
discoveries based on these models would ultimately provide
an optimum clinical perspective to conquering this wide-
spread disease.
Table 1 Summary of transgenic mouse and tumor xenograft models in translational prostate research.
Models Transgenic mouse lines:
PSA-Cre-ERT2/PTEN
AP-OX NHPrE1- and BHPrE1-
tissue recombination-
xenografting model
Prostatic
organoid
culture
PDX
Genes PTEN NHPrE1 (CD133high/
CD44high/OCT4high/
PTENhigh)
BHPrE1 (p63high/
p53high/(p21WAF1)high/
RBhigh)
Research
direction
Genetic
experiments
Tumor
microenvironment
Functional remodeling
of human prostate
tissues and tumors
Tumor behavior:
proliferation,
invasiveness, and
drug sensitivity
Interactions
between PCa cells
and tumor
microenvironment
Application 1. Clarify the
functions of
particular genes
in prostate
development and
carcinogenesis
2. Study preventive
and therapeutic
approaches in vivo
1. Study of the
curative effects of
novel clinical trial
drugs on tumor
cell proliferation
and regional lymph
node metastasis
2. Rapid screen of
potential
therapeutics
Investigate the
mechanisms associated
with human prostatic
regeneration,
pathogenesis,
and carcinogenesis
Manufacture
targeted drugs
Angiogenesis,
identification of
castrate-resistant
stem-like cells,
effects of anti-
androgen therapies,
and interactions
between tumor
cells and the bone
microenvironment
Limitations No distant
metastases even
after PTEN ablation
for extended periods
1. Low tumor
take rates
2. Only successful
in case of highly
advanced
malignancies
Difficulty in
propagating
tumor cells
for a long
time in vitro
1. Advanced
cancer organoids
grow worse
2. Low success
rates
1. Organoids from
advanced cancers
grow worse
2. Soaring expenses
and abundant
human resources
3. Low success rates
Representative
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